We present our initial experience of applying HP 13C pyruvate MRI in patients with renal tumors. Distinct tumor metabolic pattern and heterogeneity can be observed on HP 13C pyruvate MRI. Our data from subjects with two injections also suggests that the metabolite measurements are reproducible. This initial experience paves the way for this metabolic imaging technique to be applied for differentiating between benign renal tumors, low grade RCCs and high grade RCCs.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords